Embecta (EMBC) vs Anbio Biotechnology (NNNN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Embecta (EMBC) has outperformed Anbio Biotechnology (NNNN) over the past year, losing 58.4% versus a loss of 85.1%. Embecta is the larger company by market cap ($325.8 million vs $202.8 million), about 1.6 times the size. On valuation, Embecta trades at a lower trailing P/E (3.9x vs 30.8x for Anbio Biotechnology).
Embecta pays a dividend yielding 8.00%, while Anbio Biotechnology does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EMBC | NNNN |
|---|---|---|
| Share price | $5.75 | $4.62 |
| Market cap | $325.79M | $202.78M |
| 1-day change | -2.71% | -5.71% |
| YTD return | -51.60% | -84.64% |
| 1-year return | -58.39% | -85.09% |
| P/E ratio (TTM) | 3.91 | 30.80 |
| Forward P/E | 3.26 | — |
| EPS (TTM) | $1.47 | $0.15 |
| Dividend yield | 8.00% | 0.00% |
| Annual dividend | $0.46 | $0.00 |
| 52-week high | $14.91 | $44.73 |
| 52-week low | $2.77 | $4.55 |
| Distance from 52-week high | -61.44% | -89.67% |
| Analyst consensus | none | — |
| Avg. price target upside | -30.43% | — |
| Average volume | 1.37M | 146.84K |
| Shares outstanding | 56.66M | 43.89M |
| Employees | 1,850 | 27 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EMBC has outperformed NNNN by 26.7 percentage points over the past year.
- Anbio Biotechnology trades at a higher earnings multiple (30.8x vs 3.9x trailing P/E).
- Embecta offers a meaningfully higher dividend yield (8.00% vs 0.00%).
About Embecta
EMBC stock →Embecta Corp., a medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally. The company's products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.
Health Care · Medical/Dental Instruments · 1,850 employees
About Anbio Biotechnology
NNNN stock →Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally. The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction solutions; and SARS-CoV-2 and SARS-CoV-2/Flu A/Flu B antigen rapid test kits.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 27 employees
EMBC vs NNNN FAQ
Which is bigger, Embecta or Anbio Biotechnology?
Embecta (EMBC) is larger, with a market capitalization of $325.79M compared with $202.78M for Anbio Biotechnology (NNNN).
Which stock has performed better over the past year, EMBC or NNNN?
EMBC returned -58.39% over the past 12 months, compared with -85.09% for NNNN (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, EMBC or NNNN?
EMBC has the lower trailing P/E at 3.9, versus 30.8 for NNNN. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Embecta or Anbio Biotechnology?
Embecta pays a dividend yielding 8.00%, while Anbio Biotechnology does not currently pay a regular dividend.
Are Embecta and Anbio Biotechnology in the same industry?
Both are in the Health Care sector, but in different industries: Medical/Dental Instruments for Embecta and Biotechnology: In Vitro & In Vivo Diagnostic Substances for Anbio Biotechnology.